What is the half-life of Triptorelin?

Triptorelin has a half-life of ~3 hours (immediate release); depot formulations provide sustained release over weeks, which is why it's typically administered single dose or as prescribed (depot formulations monthly/quarterly) for optimal therapeutic effect.

How do I reconstitute Triptorelin?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Approved

Triptorelin

Also known as: GnRH Agonist, Trelstar, Decapeptyl, Diphereline, Triptorelin Pamoate

Overview

Key Facts

Primary Goal: A synthetic GnRH agonist decapeptide analog with a D-Trp6 substitution that provides greatly enhanced potency and resistance to enzymatic degradation compared to native GnRH

A synthetic GnRH agonist decapeptide analog with a D-Trp6 substitution that provides greatly enhanced potency and resistance to enzymatic degradation compared to native GnRH. After an initial stimulatory phase, chronic administration causes pituitary GnRH receptor downregulation, leading to profound suppression of gonadotropins and sex steroid production. Half-Life ~3 hours (immediate release); depot formulations provide sustained release over weeks Typical Dose 100–200 mcg Frequency single dose or as prescribed (depot formulations monthly/quarterly) Cycle Length Single dose in PCT protocols; months to years in clinical applications

Dosing Information

Half-Life

~3 hours (immediate release); depot formulations provide sustained release over weeks

Typical Dose

100–200 mcg

Frequency

single dose or as prescribed (depot formulations monthly/quarterly)

Cycle Length

Single dose in PCT protocols; months to years in clinical applications

Administration Routes:

subcutaneousintramuscular

Storage & Reconstitution

Unreconstituted (Powder)

Temperature20–25°C (68–77°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature20–25°C (68–77°F)

Duration2-4 weeks

Research Summary

Approved

Triptorelin is FDA-approved under multiple brand names (Trelstar, Decapeptyl) for advanced prostate cancer, endometriosis, and central precocious puberty. In the peptide research community, it has gained interest due to a small 2009 study by Tan & Scally suggesting that a single low-dose (100 mcg) injection could significantly stimulate endogenous testosterone recovery after anabolic steroid-induced hypogonadism. While this application remains under-studied, the compound's clinical pharmacology is well-established.